Search results
Showing 46 to 60 of 1376 results for 0
Surgical insertion of a catheter-based intravascular microaxial flow pump for cardiogenic shock
In development Reference number: GID-IPG10461 Expected publication date: 25 March 2026
Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria (TA1010)
Evidence-based recommendations on danicopan (Voydeya) with ravulizumab (Ultomiris) or eculizumab (Soliris) for paroxysmal nocturnal haemoglobinuria in adults with residual haemolytic anaemia.
In development Reference number: GID-IPG10318 Expected publication date: 25 March 2026
Percutaneous insertion of a catheter-based intravascular microaxial flow pump for cardiogenic shock
In development Reference number: GID-IPG10404 Expected publication date: 25 March 2026
Ambulight PDT for the treatment of non-melanoma skin cancer (MTG6)
Evidence-based recommendations on Ambulight PDT for the treatment of non-melanoma skin cancer.
This quality standard covers care for pregnant women who may be at risk of, or have symptoms and signs of, starting labour and giving birth early (preterm). It describes high-quality care in priority areas for improvement.
View quality statements for QS135Show all sections
Sections for QS135
- Quality statements
- Quality statement 1: Providing information about potential signs and symptoms of preterm labour
- Quality statement 2: Prophylactic vaginal progesterone and prophylactic cervical cerclage
- Quality statement 3: Information for women having a planned preterm birth
- Quality statement 4: Tocolysis for women between 26+0 and 33+6 weeks of pregnancy
- Quality statement 5: Corticosteroids for women between 24+0 and 33+6 weeks of pregnancy
- Quality statement 6: Magnesium sulfate for women between 24+0 and 29+6 weeks of pregnancy
- Update information
Evidence-based recommendations on aflibercept (Eylea) for treating sight problems caused by macular oedema from central retinal vein occlusion in adults.
Awaiting development Reference number: GID-TA10393 Expected publication date: TBC
Evidence-based recommendations on sotorasib (Lumykras) for previously treated KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults.
Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults.
Evidence-based recommendations on olaparib (Lynparza) for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy in adults.
Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron (ESNM69)
Summary of the evidence on netupitant/palonosetron to prevent chemotherapy induced nausea and vomiting to inform local NHS planning and decision-making
Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475)
Evidence-based recommendations on dimethyl fumarate (Skilarence) for treating moderate to severe plaque psoriasis in adults.
Regorafenib for previously treated advanced hepatocellular carcinoma (TA555)
Evidence-based recommendations on regorafenib (Stivarga) for treating advanced hepatocellular carcinoma in adults who have had sorafenib.
In development Reference number: GID-IPG10392 Expected publication date: TBC